← Back to Search

Hormone Therapy

BMS-986278 for Healthy Subjects

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to day 53

Awards & highlights

Study Summary

This trial studies how a drug affects contraceptive use in healthy women.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to day 53

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to day 53

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to day 53 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC [INF])

Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])

Maximum observed plasma concentration (Cmax)

Secondary outcome measures

Apparent total body clearance after extravascular administration (CL/F)

Number of Participants with AEs leading to discontinuation

Number of Participants with Adverse Events (AEs)

+7 more

Trial Design

2Treatment groups

Experimental Treatment

Group I: Treatment B: BMS-986278/DRSP/EEExperimental Treatment2 Interventions

Group II: Treatment A: DRSP/EEExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

BMS-986278

2023

Completed Phase 2

~750

Drospirenone/Ethinyl Estradiol

2023

Completed Phase 1

~40

Do I qualify?Apply below to find out

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,463 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are participants aged 80 or younger admissible for this research trial?

"According to the selection criteria for this research, only those aged 18 and above but below 65 can be admitted."

Answered by AI

May I be considered as a potential participant of this research endeavor?

"To qualify for this trial, potential participants must be in good health and between 18-65 years old. Ultimately, 36 people are being recruited to the study."

Answered by AI

Has the FDA officially authorized the use of Treatment A: DRSP/EE?

"Treatment A: DRSP/EE received a rating of 1 on our safety scale since this is the first trial exploring its efficacy and security."

Answered by AI

How many individuals are enrolled in this experiment?

"Affirmative. Clinicaltrials.gov reveals that this research endeavor, which was initially advertised on August 18th 2023, is actively looking for participants. A total of 36 patients must be gathered from 1 clinical centre."

Answered by AI

Are there any available positions for participants in this trial?

"Yes, the information available on clinicaltrials.gov suggests that this medical trial is currently open for recruitment and requires 36 patients from 1 medical facility. The study was originally posted on August 18th 2023 with its most recent update occurring September 28th of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants

2023. "A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05985590.